Saturday, October 16, 2021

Pfizer jab 95.8% effective against Covid-19, says Israel health ministry

The jab is also said to be 99.2% effective against serious illness and 98.9% effective in preventing death.

Other News

Israel’s health ministry said Saturday recent data from its aggressive coronavirus vaccination campaign showed two doses of the Pfizer/BioNTech jab were nearly 96% effective against infection.

Israel’s inoculation campaign is regarded as the world’s fastest, with one dose of the Pfizer/BioNTech vaccine administered to 4.25 million people out of its nine million-strong population since December, according to the latest health ministry figures.

Some 2.88 million people have received the recommended full course of two jabs.

The health ministry said on Saturday the vaccine had proved 95.8% effective in preventing coronavirus infection among those vaccinated two weeks after receiving their second shot compared to unvaccinated people, according to data compiled up to Feb 13.

It added the jab was 99.2% effective against serious illness and 98.9% effective in preventing death.

For those tested one week after receiving a second jab, the vaccine was 91.9% effective against infection, 96.4% effective in preventing serious illness and 94.5% in preventing death.

“Our goal is to continue vaccinating all our population aged 16 and up, to reach a wide coverage of the population that will enable us to return to our much missed routines,” health ministry director-general Hezi Levi said in a statement Saturday.

The jab developed by US pharma giant Pfizer and its German partner BioNTech is based on novel mRNA technology and was the first vaccine against Covid-19 to be approved in the West late last year.

Israel, which has one of the world’s most sophisticated medical data systems, secured a substantial stock of the Pfizer/BioNTech vaccine by paying above market price and by striking a data-sharing deal with the US company.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles